论文部分内容阅读
目的探讨每3个月静滴唑来膦酸4mg对绝经后乳腺癌患者口服来曲唑内分泌治疗骨质疏松的防治作用。方法 40例绝经后激素受体阳性、病情稳定的乳腺癌患者,随机分为二组,每组20例,观察组用来曲唑2.5mg/d口服,唑来膦酸4mg静滴,每3个月1次,对照组仅用来曲唑2.5mg/d口服。每3个月进行疼痛评分,每年腰椎骨密度测定1次,观察患者有无骨折及骨转移。结果 40例患者均随访2年,治疗组的骨骼疼痛、骨密度与对照组比较差异有统计学意义(P<0.05),二组骨折及骨转移的发生率比较差异无统计学意义(P>0.05)。结论唑来膦酸每3个月静脉滴注4mg对绝经后乳腺癌患者内分泌治疗过程中骨质疏松的防治具有临床应用价值,能明显改善患者的生存质量。
Objective To investigate the preventive and therapeutic effects of letrozole 4 mg every 3 months on the treatment of osteoporosis by oral letrozole in postmenopausal women with breast cancer. Methods Forty cases of postmenopausal hormone receptor positive patients with stable breast cancer were randomly divided into two groups (n = 20 in each group). The observation group was treated with 2.5 mg / d of oxazole and 4 mg of zoledronic acid every 3 Once a month, the control group was only used for oral 2.5 mg / d. The pain was scored every 3 months, and the lumbar spine BMD was measured once every year to observe the presence or absence of fractures and bone metastases. Results All the 40 patients were followed up for 2 years. The skeletal pain and bone mineral density in the treatment group were significantly different from those in the control group (P <0.05). There was no significant difference in the incidence of fracture and bone metastasis between the two groups (P> 0.05). Conclusion The intravenous infusion of 4 mg zoledronic acid every 3 months has clinical value in the prevention and treatment of osteoporosis during endocrine therapy in postmenopausal women with breast cancer. It can significantly improve the quality of life of patients.